While reporting financial results for the first quarter on Thursday, Charles River Laboratories International, Inc. (CRL) slashed its earnings and revenue growth guidance for the full-year 2020, due to the global COVID-19 pandemic and its expected impact on the operations, client demand, and financial results.
For fiscal 2020, the company now projects earnings in a range of $4.25 to $4.60 per share and adjusted earnings in a range of $6.75 to $7.10 per share on revenues growth of 4.5 to 8.0 percent and organic revenues growth of 1.5 to 4.5 percent.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com